Reimbursement

A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.

Medtechs will be indirectly affected by a new law in Switzerland that unifies the amount of funding allocated to inpatient and ambulatory care.

Pharmaceutical manufacturers face unique challenges, particularly when it comes to managing thousands of complex rebate contracts and connecting the dots between contract agreements and business performance.

Neurocrine will launch Crenessity for adults and children with classic congenital adrenal hyperplasia in less than a week, with pricing available then, adding its second commercial product.

A pair of Humira biosimilars, including one from Sandoz, will no longer be covered on one of OptumRx’s 2025 US commercial formularies.

A new methods guide from Canada’s health technology assessment agency should help drug sponsors generate and report appropriate clinical evidence.

England’s National Health Service has yet to meet targets for speedy availability of anticancer drugs that have gone through an early access scheme and then been green-lit by NICE.

The proposal states that Part D plans could define "obesity" for coverage determination, but CMS said overly restrictive criteria would be inconsistent with formulary review requirements and step-therapy would not be allowed.

Germany’s governing coalition may have folded, but embattled health minister Lauterbach has championed his hospital reform bill to the last. Now voted through in the upper house of parliament, the bill to reform diagnosis related groups and hospital care delivery will come into force on 1 January.

A new, international group of health technology assessment agencies will work together on topics related to health economic methods that could include dynamic pricing and non-traditional ways of evaluating value in cost-effectiveness analyses.